The deal comes on the heels of a partnership with HealthVerity, through which Parexel will see its real world data (RWD) network expand by more than 330m patients across 60 health are and consumer sources.
“With this strategic partnership, Parexel aims to provide a platform that enables more innovative trial designs, which can answer more specific questions in drug development,” said Jason Martin, senior vice president, global data operations, Parexel.
As per the agreement, Parexel will incorporate Datavant’s linking and de-identification technology across its study framework – with the aim to ‘ease’ the incorporation of RWD into ‘all aspects’ of clinical research, said Martin.
“We believe Datavant’s technology provides the most data- and supplier- agnostic approach to accomplish our goal. To offer the most flexibility for our clients, we believe it is important to not limit data sources or the approaches for integrating them into study conduct,” he told us.
Datavant’s technology links de-identified data, including electronic health records (EHRs), claims, and diagnostics, in addition to genomics, wearables, socioeconomic, and behavioral data, among other sources.
Further terms of the agreement are not currently public.
Said Martin, “Datavant technology allows Parexel to innovate in the area of RWD integration while complying with data consent and data ownership restrictions. This ultimately provides the most data utility for our customers to help them enhance drug delivery to patients, without compromising patient privacy.”
Parexel also earlier this year announced a $1.7m investment into a second US headquarters, which will house several functions and more than 260 new employees.
